# IRulya Therapeutics Inc.: overview IRLA · Nasdaq · CIK 1662774 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/irla.md) · [Financials](/companies/irla/financials.md) · [Filings](/companies/irla/filings.md) · [Insiders](/companies/irla/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.13)](/filings/0001193125-25-277529.md) | not reported | [(3.42)](/filings/0001193125-26-217098.md) | [(68.75)](/filings/0001193125-26-352201.md) | [(0.25)](/filings/0001193125-25-277529.md) | not reported | [2.88](/filings/0001193125-26-217098.md) | [(12.31)](/filings/0001193125-26-352201.md) | | Free cash flow | $m | [(7.3) d](/filings/0001193125-25-277529.md) | [(7.7) d](/filings/0001193125-26-151364.md) | [(9.7)](/filings/0001193125-26-217098.md) | [(11.5) d](/filings/0001193125-26-352201.md) | [(10.0) d](/filings/0001193125-25-277529.md) | [(10.5) d](/filings/0001193125-26-151364.md) | [(7.6)](/filings/0001193125-26-217098.md) | [(18.9) d](/filings/0001193125-26-352201.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.03)](/filings/0000950170-23-008148.md) | [(1.54)](/filings/0000950170-24-039440.md) | [(0.84)](/filings/0001662774-25-000012.md) | [(1.31)](/filings/0001193125-26-151364.md) | [(1.68)](/filings/0001193125-26-151364.md) | | Free cash flow | $m | [(63.1)](/filings/0000950170-23-008148.md) | [(44.2)](/filings/0000950170-24-039440.md) | [(18.5)](/filings/0001662774-25-000012.md) | [(32.2)](/filings/0001193125-26-151364.md) | [(41.8)](/filings/0001193125-26-151364.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/irla/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $12.6m | 69,967 | | New +69,967 | | [TUDOR INVESTMENT CORP ET AL](/funds/923093.md) | 2026-06-30 | $2.1m | 117,800 | Put | New +117,800 | | [TUDOR INVESTMENT CORP ET AL](/funds/923093.md) | 2026-06-30 | $2.1m | 115,800 | Call | New +115,800 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $1.3m | 72,251 | | New +72,251 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $1.3m | 70,779 | | New +70,779 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.0m | 55,000 | Call | New +55,000 | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $734.4k | 40,375 | | New +40,375 | | [Shay Capital LLC](/funds/1723643.md) | 2026-06-30 | $329.3k | 17,468 | | New +17,468 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $253.0k | 13,911 | | New +13,911 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $230.0k | 12,642 | | New +12,642 | ## Recent filings [All 450 filings](/companies/irla/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 12:49 ET | [8-K](/filings/0001193125-26-424731.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-424731 | | 2026-10-09 | 11:59 ET | [8-K](/filings/0001193125-26-418538.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-418538 | | 2026-10-06 | 20:57 ET | [8-K](/filings/0001193125-26-415730.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-415730 | | 2026-10-02 | 11:30 ET | [8-K](/filings/0001193125-26-411260.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-411260 | | 2026-09-14 | 20:30 ET | [8-K](/filings/0001193125-26-390652.md) | 2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-390652 | | 2026-09-04 | 12:30 ET | [8-K](/filings/0001193125-26-382838.md) | 3.01 Delisting notice | 0001193125-26-382838 | | 2026-08-27 | 20:30 ET | [8-K](/filings/0001193125-26-371389.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-371389 | | 2026-08-25 | 12:30 ET | [DEF 14A](/filings/0001193125-26-364220.md) | Proxy statement, period 2026-10-06 | 0001193125-26-364220 | | 2026-08-17 | 10:01 ET | [8-K](/filings/0001193125-26-353141.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-353141 | | 2026-08-14 | 20:05 ET | [10-Q](/filings/0001193125-26-352201.md) | Quarterly report, period 2026-06-30 | 0001193125-26-352201 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-151364.md), filed Apr 10, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1662774 - Tickers: IRLA, QNCX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.